Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuanchen Liu

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
JAMA|July 20, 2016
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysisSuetonia C Palmer, Dimitris Mavridis, Antonio Nicolucci, et al.
Journal of Medical Virology|February 19, 2024
Type-II IFN inhibits SARS-CoV-2 replication in human lung epithelial cells and ex vivo human lung tissues through indoleamine 2,3-dioxygenase-mediated pathwaysDong Yang, Jasper Fuk-Woo Chan, Chaemin Yoon, et al.
Science Advances|January 20, 2023
Altered host protease determinants for SARS-CoV-2 OmicronJasper Fuk-Woo Chan, Xiner Huang, Bingjie Hu, et al.
Nature Communications|November 26, 2025
Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolutionMinxiang Xie, Yinong Qiu, Xiaoyu Zhao, et al.
Nature|January 21, 2022
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 OmicronHuiping Shuai, Jasper Fuk-Woo Chan, Bingjie Hu, et al.
Cell Reports. Medicine|September 9, 2022
Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2Jasper Fuk-Woo Chan, Bingjie Hu, Yue Chai, et al.
Research Square|November 28, 2024
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoHin Chu, Huiping Shuai, Jingxin Qiao, et al.
Ebiomedicine|August 14, 2023
The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5Huiping Shuai, Jasper Fuk-Woo Chan, Bingjie Hu, et al.
Ebiomedicine|December 15, 2023
Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tractBingjie Hu, Jasper Fuk-Woo Chan, Yuanchen Liu, et al.
Nature Communications|December 15, 2025
Author Correction: An orally available M<sup>pro</sup>/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoHuiping Shuai, Jingxin Qiao, Chaemin Yoon, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
JAMA|July 20, 2016
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysisSuetonia C Palmer, Dimitris Mavridis, Antonio Nicolucci, et al.
Journal of Medical Virology|February 19, 2024
Type-II IFN inhibits SARS-CoV-2 replication in human lung epithelial cells and ex vivo human lung tissues through indoleamine 2,3-dioxygenase-mediated pathwaysDong Yang, Jasper Fuk-Woo Chan, Chaemin Yoon, et al.
Science Advances|January 20, 2023
Altered host protease determinants for SARS-CoV-2 OmicronJasper Fuk-Woo Chan, Xiner Huang, Bingjie Hu, et al.
Nature Communications|November 26, 2025
Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolutionMinxiang Xie, Yinong Qiu, Xiaoyu Zhao, et al.
Nature|January 21, 2022
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 OmicronHuiping Shuai, Jasper Fuk-Woo Chan, Bingjie Hu, et al.
Cell Reports. Medicine|September 9, 2022
Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2Jasper Fuk-Woo Chan, Bingjie Hu, Yue Chai, et al.
Research Square|November 28, 2024
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoHin Chu, Huiping Shuai, Jingxin Qiao, et al.
Ebiomedicine|August 14, 2023
The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5Huiping Shuai, Jasper Fuk-Woo Chan, Bingjie Hu, et al.
Ebiomedicine|December 15, 2023
Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tractBingjie Hu, Jasper Fuk-Woo Chan, Yuanchen Liu, et al.
Nature Communications|December 15, 2025
Author Correction: An orally available M<sup>pro</sup>/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoHuiping Shuai, Jingxin Qiao, Chaemin Yoon, et al.
Pageof 4